Pediatric Kidney Transplant

Induction therapy is essential to prevent graft rejection in pediatric kidney transplantation, with basiliximab and ATG being the most widely used agents. Comparative evidence to guide the selection of the most effective induction therapy in pediatric kidney transplantation remains limited. Therefore, we will conduct a retrospective cohort study in pediatric (<18 years) kidney transplant recipients at King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, Saudi Arabia, in patients who received induction with either basiliximab or ATG. We will assess these groups for clinical outcomes.

Rezqah Aldhaferi, Sulaiman Alrddadi.